1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 0, 1-31 (2018).
2. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 95, S161-192 (2006).
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 365, 2473-2483 (2011).
4. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RHJ, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer : a randomised phase 2 trial. Lancet Oncol. 16, 87–97 (2015).
5. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 4, 287-313 (2009).
6. Kurman RJ and Shih leM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am.J.Surg.Pathol. 34, 433-443 (2010).
7. Yoshimoto M, Tokuda A, Yaginuma Y. The origin and carcinogenesis of ovarian carcinoma. 熊本大学医学部保健学科紀要第14号, 22-32 (2018).
8. Cobb LP, Gaillard S, Wang Y, Shih IeM, Secord AA. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. 2, 1 (2015).
9. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 164, 1511-1518 (2004).
10. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
11. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363, 1532-1543 (2010).
12. Khabele, D. KRAS in Ovarian Cancer. My Cancer Genome https://www.mycancergenome.org/content/disease/ovarian-cancer/kras/ (2015).
13. Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 226, 413-420 (2012).
14. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 231, 449-456 (2013).
15. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 221, 49-56 (2010).
16. Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, et al. TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 46, 607–618 (2015).
17. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, et al. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 3, 565-569 (2013).
18. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
19. Gupta G and Massague J. Cancer metastasis: building a framework. Cell 127, 679– 695 (2006).
20. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7, 925–934 (2006).
21. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 177, 1053– 1064 (2010).
22. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17, 548–558 (2006).
23. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and IG-cams in cancer. Nat Rev. 4, 118–132 (2004).
24. He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, et al. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene 35, 468–478 (2016).
25. Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, et al. β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene 34, 2297–2308 (2015).
26. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 126, 4157–4173 (2016).
27. Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 67, 2030–2039 (2007).
28. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny HA, Salgia R, et al. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67, 1670–1680 (2007).
29. Birgersdotter A, Sandberg R, Ernberg I. Gene expression perturbation in vitro—A growing case for three-dimensional (3D) culture systems. Semin Cancer Biol. 15, 405-412 (2005).
30. Cukierman E, Pankov R, Yamada KM. Cell interactions with three-dimensional matrices. Curr Opin Cell Biol. 14, 633-639 (2002).
31. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 7, 211-224 (2006).
32. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 22, 287-309 (2006).
33. Kusamori K, Nishikawa M, Takahashi Y, Takakura Y. Development of multicellular spheroid for cell-based therapy. Drug Delivery System 28, 45-53 (2013).
34. Lin RZ and Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J. 3, 1172-1184 (2008).
35. Berking C and Herlyn M. Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol Histopathol. 16, 669–674 (2001).
36. Weigelt B, Ghajar CM, Bissell MJ. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev. 69-70, 42-51 (2014).
37. White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 0, 184-192 (2014).
38. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 93, 170–181 (2004).
39. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 6, 11 (2007).
40. Yamada KM and Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 130, 601-610 (2007).
41. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res.72, 2457-2467 (2012).
42. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell 170, 17-33 (2017).
43. Ali A, Li X. Oncogenic molecular pathways: mechanisms, mutations and inhibitors.Ann Hematol Oncol. 3, 1108 (2016).
44. Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res. 20, 2516-2522 (2014).
45. Mullany LK, Richards JS. Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology. 153, 1585–1592 (2012).
46. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 205, 858-862 (2009).
47. Birgisson H, Edlund K, Wallin U, Pahlman L, Kultima HG, Mayrhofer M, et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer 15, 125 (2015).
48. Yoshida M, Taguchi A, Kawana K, Adachi K, Kawata A, Ogishima J, et al. Modification of the tumor microenvironment in KRAS or c-MYC-induced ovarian cancer-associated peritonitis. PLoS One 11, e0160330 (2016).
49. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 10, 336–346 (2011).
50. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 107, 8788–8793 (2010).
51. Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 39, 23-31 (2011).
52. Ishii N. Progress of research and development of MAPK pathway inhibitors. Folia Pharmacol. Jpn. 141, 15-21 (2013).
53. Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 8, 2251-2259 (2015).
54. Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 17, 154 (2018).
55. Weart TC, Miller KD, Simone CB 2nd. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. Cancer Manag Res. 10, 647-652 (2018).
56. Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, et al. Trametinib for progressive pediatric low-grade gliomas. J Neurooncol. 1–10 (2018).
57. Dhillon S. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation. Target Oncol. 11, 417-428 (2016).
58. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 377, 1813-1823 (2017).
59. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 14, 134–40 (2013).
60. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21, 585–591 (2000).
61. Bak SP, Walters JJ, Takeya M, Conejo-Garcia JR, Berwin BL. Scavenger receptor-A–targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res. 67, 4783-4789 (2007).
62. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900-6912 (2013).
63. Bak SP, Alonso A, Turk MJ, Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol. 46, 258-268 (2008).
64. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 30, 579-594 (2013).
65. Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 193, 5327-5337 (2014).
66. Zhang Y, Nowicka A, Solley TN, Wei C, Parikh A, Court L, et al. Stromal cells derived from visceral and obese adipose tissue promote growth of ovarian cancers. PLoS One 10, e0136361 (2015).
67. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy. Nature 527, 249-253 (2015).
68. Rodenburg CJ, Cornelisse CJ, Heintz PA, Hermans J, Fleuren GJ. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 59, 317-323 (1987).
69. Braly PS. The current status of flow cytometry in gynecologic oncology. Oncology (Williston Park). 6, 23-28 discussion 31-3 (1992).
70. Cho S, Sun Y, Soisson AP, Dodson MK, Peterson CM, Jarboe EA, et al. Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model. Anticancer Res. 33, 1317-1324 (2013).
71. Khabele, D. KRAS c.35G>T (G12V) Mutation in ovarian cancer. My Cancer Genome https://www.mycancergenome.org/content/disease/ovarian-cancer/kras/37/ (2017).
72. Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, et al. Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. Oncotarget 7, 33297–33305 (2016).
73. Carlier G, Maugein A, Cordier C, Pechberty S, Garfa-Traoré M, Martin P, et al. Human fucci pancreatic beta cell lines: new tools to study Beta cell cycle and terminal differentiation. PLoS One 9, e108202 (2014).
74. Nakamura M, Shibata K, Hatano S, Sato T, Ohkawa Y, Yamada H, et al. A genome-wide analysis identifies a notch-RBP-Jκ-IL-7Rα axis that controls IL-17-producing γδ T cell homeostasis in mice. J Immunol. 194, 243–251 (2015).
75. Stack G, Jones E, Marsden M, Stacey MA, Snelgrove RJ, Lacaze P, et al. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathog. 11, 1–20 (2015).
76. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, et al. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 37, W317-322 (2009).
77. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 8, R3 (2007).
78. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: A non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 40, 478–483 (2012).
79. Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283–287 (2014).
80. Laurance S, Lemarié CA, Blostein MD. Growth arrest-specific gene 6 (gas6) and vascular hemostasis. Adv Nutr. 3, 196–203 (2012).
81. Huang RY, Antony J, Tan TZ, Tan DS. Targeting the AXL signaling pathway in ovarian cancer. Mol Cell Oncol. 4, e1263716 (2016).
82. Paccez JD, Vogelsang M, Parker MI, Zerbini LF. The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int J Cancer 134, 1024–1033 (2014).
83. Kang YH, Han SR, Kim JT, Lee SJ, Yeom YI, Min JK, et al. The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancer. Oncotarget 5, 2149–2160 (2014).
84. Lee JH, Choi SI, Kim RK, Cho EW, Kim IG. Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1. Sci Rep. 8, 10711 (2018).
85. Ueda K, Arakawa H, Nakamura Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22, 5586–5591 (2003).
86. Shin SH, Park SY, Kang GH. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Am J Pathol. 182, 1275–1285 (2013).
87. Yan X, Liu L, Li H, Huang L, Yin M, Pan C, et al. Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer. Am J Cancer Res. 6, 2323–2333 (2016).
88. Levay K, Slepak VZ. Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression. J Clin Invest. 117, 2672–2683 (2007).
89. Kucharska A, Rushworth LK, Staples C, Morrice NA, Keyse SM. Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. Cell Signal 21, 1794–1805 (2009).
90. Buffet C, Catelli MG, Hecale-Perlemoine K, Bricaire L, Garcia C, Gallet-Dierick A, et al. Dual specificity phosphatase 5, a specific negative regulator of ERK signaling, is induced by serum response factor and Elk-1 transcription factor. PLoS One 10, e0145484 (2015).
91. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 11, 385–400 (2014).
92. Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 73, 1245-1254 (2013).
93. Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res. 14, 6097-6105 (2008).
94. Kim JY, Kim H, Suk K, Lee WH. Activation of CD147 with cyclophilin a induces the expression of IFITM1 through ERK and PI3K in THP-1 cells. Mediators Inflamm. 2010, 821940 (2010).
95. Wu G, Ma Z, Cheng Y, Hu W, Deng C, Jiang S, et al. Targeting Gas6/TAM in cancer cells and tumor microenvironment. Mol Cancer. 17, 20 (2018).
96. Lee HJ, Jeng YM, Chen YL, Chung L, Yuan RH. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis. 35, 769-775 (2014).
97. Kang JS, Krauss RS. Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol Cell Biol. 16, 3370-3380 (1996).
98. Thullberg M, Gad A, Le Guyader S, Stromblad S. Oncogenic H-Ras V12 promotes anchorage-independent cytokinesis in human fibroblasts. Proc Natl Acad Sci U S A. 104, 20338-20343 (2007).
99. Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, et al. Enhanced MET translation and signaling sustains K-Ras driven proliferation under anchorage-independent growth conditions. Cancer Res. 75, 2851-2862 (2015).
100. Lehr S, Kotzka J, Avci H, Sickmann A, Meyer HE, Herkner A, et al. Identification of major ERK-related phosphorylation sites in Gab1. Biochemistry. 43, 12133-12140 (2004).
101. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 121, 4311-4321 (2011).
102. Li X, Huang Y, Jiang J, Frank SJ. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal. 20, 2145-2155 (2008).
103. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228-3237 (2012).